Discovery and development of heat shock protein 90 inhibitors as anticancer agents: A review of patented potent geldanamycin derivatives

Expert Opinion on Therapeutic Patents

Volumn 23, Issue 8, 2013, Pages 919-943

  Kim, Taehun ^a,b   Keum, Gyochang ^a,b   Pae, Ae Nim ^a,b  

^a Korea Institute of Science and Technology   (South Korea)

^b University of Science and Technology (UST)   (South Korea)

Author keywords

17 AAG; 17 DMAG; Ansamycin; Cancer; Geldanamycin; Heat shock protein 90; IPI 493; IPI 504

Indexed keywords

ABI 010; ALVESPIMYCIN; ANSAMYCIN DERIVATIVE; AT 13387; BIIB 021; BIIB 028; BORTEZOMIB; CNF 2024; GANETESPIB; GELDANAMYCIN; GELDANAMYCIN DERIVATIVE; GEMCITABINE; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HERBIMYCIN A; HSP 990; HYDROQUINONE DERIVATIVE; IMATINIB; IPI 493; IRINOTECAN; KW 2478; LUMINESPIB; MACBECIN I; MPC 3100; NOVOBIOCIN; RETASPIMYCIN; SUNITINIB; TANESPIMYCIN; UNCLASSIFIED DRUG; XL 888;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; BINDING AFFINITY; BONE MARROW DISEASE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER THERAPY; CARBAMOYLATION; CLINICAL TRIAL (TOPIC); CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; CYTOTOXICITY; DEHYDROGENATION; DEVELOPMENT; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DEGRADATION; DRUG EFFICACY; DRUG FORMULATION; DRUG STRUCTURE; DRUG SYNTHESIS; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TUMOR; HUMAN; HYDROGEN BOND; LIVER DISEASE; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; NONHUMAN; OXIDATION; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN SYNTHESIS; REVIEW; SOLID TUMOR; STREPTOMYCES HYGROSCOPICUS; STRUCTURE ACTIVITY RELATION; VIRUS REPLICATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZOQUINONES; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; NEOPLASMS; PATENTS AS TOPIC; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84880679940     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2013.780597     Document Type: Review

References (84)

1. Patel HJ, Modi S, Chiosis G, Taldone T Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment Expert Opin Drug Discov 2011;6(5):559-87
2. Bio Holding, Inc Hsp90 inhibitors and methods of use US20110201587; 2011
3. Taldone T, Sun W, Chiosis G Discovery and development of heat shock protein 90 inhibitors Bioorg Med Chem 2009;17:2225-35
4. Fukuyo Y, Hunt CR, Horikoshi N Geldanamycin and its anti-cancer activities Cancer Lett 2010;290:24-35
5. Pearl LH, Prodromou C Structure and mechanism of the Hsp90 molecular chaperone machinery Annu Rev Biochem 2006;75:271-94
6. Neckers L, Schulte TW, Mimnaugh E Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity Invest New Drugs 1999;17:361-73
7. Gorska M, Popowska U, Sielicka-Dudzin A, et al Geldanamycin and its derivatives as Hsp90 inhibitors Front Biosci 2012;17:2267-77
8. Trepel J, Mollapour M, Giaccone G, Neckers L Targeting the dynamic Hsp90 complex in cancer Nat Rev Cancer 2010;10:537-49
9. Porter JR, Ge J, Lee J, et al Ansamycin inhibitors of Hsp90: nature's prototype for anti-chaperone therapy Curr Top Med Chem 2009;9:1386-418
10. DeBoer C, Meulman PA, Wnuk RJ, Peterson DH Geldanamycin, a new antibiotic J Antibiot (Tokyo) 1970;23(9):442-7
11. Erlichman C Tanespimycin: the opportunities and challenges of targeting heat shock protein 90, Expert Opin Investig Drugs 2009;18(6):861-8
12. Omura S, Iwai Y, Takakashi Y, et al Herbimycin A, new antibiotic produced by a strain of Streptomyces J Antibiot (Tokyo) 1979;32(4):255-61
13. Tanida S, Hasegawa Y, Higashide E Macbecins I and II, new antitumor antibiotics I Producing organism, fermentation and antimicrobial activities J Antibiot (Tokyo) 1980;33(2):199-204
14. Whitesell L, Sutphin P, An WG, et al Geldanamycin-stimulated destabilization of mutated p53 is mediated by the proteasome in vivo Oncogene 1997;14:2809-16
15. Whitesell L, Mimnaugh EG, Costa BD, et al Inhibition of heat shock protein Hsp90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: Essential role for stress proteins in oncogenic transformation Proc Natl Acad Sci USA 1994;91:8324-8
16. Kosan Bioscience, Inc Method of treating multiple myeloma using 17-AAG or 17-AG or a prodrug of either in combination with a proteasome inhibitor WO2006119032 A1; 2006
17. Kim SH, Tangallapally R, Markovitz B, et al Discovery of (2S) 1-[4-(2-{6-Amino-8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl] 9H purin-9-yl}ethyl) piperidin-1-yl]-2-hydroxypropan-1-one(MPC-3100), a purine-Based Hsp90 Inhibitor J Med Chem 2012;55(17):7480-501
18. Archie NT, David SK, Mithat G, et al A Phase I dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors Clin Caner Res 2008;14:6704-11
19. Grem JL, Morrison G, Guo XD, et al Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumor J Clin Oncol 2005;23:1885-93
20. Kim YS, Alarcon SV, Lee S, et al Update on Hsp90 inhibitors in clinical trial Curr Top Med Chem 2009;9:1479-4792
21. Ramanathan RK, Trump DL, Eiseman JL, et al Phase I pharmacokinetic- pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers Clin Cancer Res 2005;11:3385-91
22. Goetz MP, Toft D, Reid J, et al Phase I trial of 17-allylamino-17- demethoxygeldanamycin in patients with advanced cancer J Clin Oncol 2005;23:1078-87
23. Banerji U, O'Donnell A, Scurr M, et al Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino-17-demethoxygeldanamycin in patients with advanced malignancies J Clin Oncol 2005;23:4152-61
24. Arlander SJ, Eapen AK, Vroman BT, et al Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress J Biol Chem 2003;278:52572-7
25. Haluska P, Toft DO, Steinmetz SM, et al A phase I trial of gemcitabine (Gem), 17-allylaminogeldanamycin (17-AAG) and cisplatin (CDDP) in solid tumor patients J Clin Oncol (Meeting Abstracts) 2004;22:3058
26. Richardson PG, Badros AZ, Jagannath S, et al Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma Br J Haematol 2010;150(4):428-37
27. Tian ZQ, Liu Y, Zhang D, et al Synthesis and biological activities of novel 17-aminogeldanamycin derivatives Bioorg Med Chem 2004;12:5317-29
28. Glaze ER, Lambert AL, Smith AC, et al Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance Cancer Chemother Pharmacol 2005;56:637-47
29. Infinity pharmaceuticals, Inc Analogs of benzoquinone-containing ansamycins and methods of use thereof US20060019941; 2006
30. Floris G, Maria DR, Agnieszka W, et al The heat shock protein 90 inhibitor IPI-504 induces KIT degradation, tumor shrinkage, and cell proliferation arrest in xenograft models of gastrointestinal stromal tumors Mol Cancer Ther 2011;10(10):1897-908
31. David S, Jagannath S, Vesole DH, et al A Phase I study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma Leukemia Lymphoma 2011;52(12):2308-15
32. Floris G, Raf S, Agnieszha W, et al The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations Clin Cancer Res 2011;17(17):5604-14
33. Stebbins CE, Russo AA, Schneider C, et al Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent Cell 1997;89:239-50
34. Prodromou C, Roe SM, O'Brien R, et al Identification and structural characterization of the ATP/ADPbinding site in the Hsp90 molecular chaperone Cell 1997;90:65-75
35. Roe SM, Prodromou C, O'Brien R, et al Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin J Med Chem 1999;42:260-6
36. Schnur RC, Corman ML, Gallaschun RJ, et al erbB-2 Oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure-activity relationships J Med Chem 1995;38:3813-20
37. Edward GM, Chavancy C, Neckers L Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin J Biol Chem 1996;271(37):22796-801
38. De boer Peterson DH Geldanamycin and process for producing same US3595995; 197139 University of illinois foundation Biologically active compounds US3987035; 1976
39. Takeda chemical Industries, Ltd Macbecin derivatives US4421687; 1983
40. Takeda chemical Industries, Ltd Antibiotic TAN-420 US4540517; 1985
41. Kaken chemical Co., Ltd Geldanamycin derivatives and antitumor drug US4261989; 1981
42. Schnur RC, Corman ML, Gallaschun RJ, et al erbB-2 Oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure-activity relationships J Med Chem 1995;38:3813-20
43. Pfizer, Inc Ansamycin derivatives as antioncogene and anticancer agents US5932566; 1999
44. Rastelli G, Tian ZQ, Wang Z, et al Structure-based design of 7-carbamate analogs of geldanamycin Bioorg Med Chem Lett 2005;15:5016-21
45. Pfizer, Inc Bicyclic ansamycins US5387584; 1995
46. Schnur RC, Corman ML, Gallaschun RJ, et al erbB-2 Oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure-activity relationships J Med Chem 1995;38:3813-20
47. Santi D, Myles DC, Tian ZQ, et al Benzoquinone ansamycins US20030114450 A1; 2003
48. Kosan Bioscience, Inc Benzoquinone ansamycins US20090111869 A1; 2009
49. Conforma Therapeutics Corp Process for preparing 17-allyl aminogeldanamycin (17-AAG) and other ansamycins WO2003026571; 2003
50. Pfizer, Inc Process to prepare and isolate geldanamycin WO2003072794; 2003
51. Lin Zhang Ansamycins having improved pharmacological and biological properties US20050267122 A1; 2005
52. Conforma Therapeutics Corp Ansamycins having improved pharmacological and biological properties US7465718 B2; 2008
53. Conforma Therapeutics Corp Compositions containing ansamycin WO2007064926; 2007
54. O' Keeffe B, Fong Y, Chen D, et al Requirement for a kinase-specific chaperone pathway in the production of a Cdk9/Cyclin T1 heterodimer responsible for P-TEFb-mediated Tat stimulation of HIV-1 transcription J Biol Chem 2000;275(1):279-87
55. Huezo H, Vilenchik M, Rosen N, Chiosis G Microtiter cell-based assay for detection of agents that alter cellular levels of Her2 and EGFR Chem Biol 2003;10(7):629-34
56. Abraxis bioscience, Inc Geldanamycin derivatives and pharmaceutical compositions thereof WO2007059116 A2; 2007
57. Li LH, Clark TD, Cowie CH, Rinehart KL Effects of geldanamycin and its derivatives on RNA-directed DNA polymerase and infectivity of rauscher leukemia virus Cancer Treat Rep 1997;61(5):815-24
58. Wright JL, Porter JR Hydroquinone ansamycin formulations US20080255008 A1; 2008
59. Schnur RC, Corman ML, Gallaschun RJ, et al Inhibition of the oncogene product p195(erbB-2) in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives J Med Chem 1995;38(19):3806-12
60. Kelland LR, Sharp SY, Rogers PM, et al DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, and inhibitor of heat shock protein 90 J Natl Cancer Inst 1999;91(22):1940-9
61. Seow HA, Penketh PG, Belcourt MF, et al Nuclear overexpression of NAD(P) H: quinone oxidoreductase 1 in Chinese hamster ovary cells increase the cytotoxicity of mitomycin C under aerobic and hypoxic condition J Biol Chem 2004;279(30):31606-12
62. Ge J, Normant E, Porter JR, et al Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90 J Med Chem 2006;49(15):4606-15
63. Guo W, Reigan P, Siegal D, et al Formation of 17-Allylamino- Demethoxygeldanamycin Hydroquinone by NAD(P)H: quinone Oxidoreductase 1: Role of 17-AAG Hydroquinone in Heat Shock Protein 90 Inhibition Cancer Res 2005;65:10006-15
64. Abraxis bioscience, Inc Derivatives of 18-amino substituted analogs of the geldanamycin hydroquinone with cytotoxicity activity for the treatment of cancer WO2008061134; 2008
65. Institute of medicinal biotechnology academy of medical science C-19 modified geldanamycin (GDM) derivatives and preparation method thereof CN102391183; 2012
66. Institute of medicinal biotechnology academy of medical science Geldanamycin biosynthetic analogue 19-O-glycyl geldanamycin CN101792418; 2010
67. Korea research institute of bioscience and biotechnology Geldanamycin derivatives by modification of biosynthetic genes WO2008038877 A1; 2008
68. Korea research institute of bioscience and biotechnology Geldanamycin derivatives, pharmaceutically acceptable salt thereof, preparation method thereof and agent for the prevention and treatment of tumor containing the same as an active ingredient WO2008038964; 2008
69. Korea research institute of bioscience and biotechnology Modified microorganisms of geldanamycin biosynthesis regulator genes and the method for producing geldanamycin using the same KR2010096502; 2010
70. Korea research institute of bioscience and biotechnology Cancer prevention and treatment containing the novel geldanamycin derivative, the pharmaceutically acceptable salt thereof, and the manufacturing method thereof and this as active ingredient KR20120482419; 2012
71. Institute of medicinal biotechnology, Chinese academy of medical science Set of geldanamycin derivatives and their preparation methods US20100311694 A1; 2010
72. Eichner S, Floss HG, Sasse F, Kirschning A New, highly active nonbenzoquinone geldanamycin derivatives by using mutasynthesis Chembiochem 2009;10:1801-5
73. Knobloch T, Drager G, Collisi W, et al Unprecedented deoxygeneration at C-7 of the ansamitocin core during mutasynthetic biotransformations Beilstein J Org Chem 2012;8:861-9
74. Eichner S, Eichner T, Floss HG, et al Broad substrate specificity of the amide synthase in S hygroscopicus-New 20-membered macrolactones derived from geldanamycin J Am Chem Soc 2012;134:1673-9
75. Takatsu T, Ohtsuki M, Muramatsu A, et al Reblastatin, a novel benzenoid ansamycin-type cell cycle inhibitor J Antibiot (Tokyo) 2000;53(11):1310-12
76. Kosan Biosciences, Inc Method for treating diseases using Hsp90-inhibiting agents in combination with antimetabolites WO2005002506; 2005
77. Kosan Biosciences, Inc Method for treating diseases using Hsp90-inhibiting agents in combination with antimitotics WO2005000314; 2005
78. Kosan Biosciences, Inc Method for treating diseases using Hsp90-inhibiting agents in combination with antibiotics WO2005000214; 2005
79. Kosan Biosciences, Inc Method for treating diseases using Hsp90-inhibiting agents in combination with immunosuppressants WO2004108080; 2004
80. Indian institute of science Polynucleotide sequence, processes, composition and methods thereof WO2011154895 A2; 2011
81. Chroma therapeutics, Ltd Pyrrolo[2,3-d] pyrimidines as inhibitors of Hsp90 WO2010043867; 2010
82. Chiang AN, Valderramos JC, Balachandran R, et al Select pyrimidinones inhibit the propagation of the malarial parasite Plasmodium falciparum Bioorg Med Chem 2009;17(4):1527-33
83. University of Pittsburgh Benzoquinone ansamycins for the treatment of cardiac arrest and stroke US6174875 B1; 2001
84. Max-planck-gesellschaft zur forderung der wissenschaften ev Compounds that inhibit Hsp90 and stimulate Hsp70, useful in the prevention or treatment of diseases associated with protein aggregation and amyloid formation WO2002094259; 2002